<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Epilepsy Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Epilepsy Res</journal-id>
<journal-title-group>
<journal-title>Journal of Epilepsy Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2233-6249</issn>
<issn pub-type="epub">2233-6257</issn>
<publisher>
<publisher-name>Korean Epilepsy Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32509551</article-id>
<article-id pub-id-type="pmc">7251340</article-id>
<article-id pub-id-type="doi">10.14581/jer.19017</article-id>
<article-id pub-id-type="publisher-id">jer-19017</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>SCN8A</italic> Mutation in Infantile Epileptic Encephalopathy: Report of Two Cases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fatema</surname>
<given-names>Kanij</given-names>
</name>
<degrees>FCPS</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rahman</surname>
<given-names>Md Mizanur</given-names>
</name>
<degrees>FCPS</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faruk</surname>
<given-names>Omar</given-names>
</name>
<degrees>MBBS</degrees>
</contrib>
<aff id="af1-jer-19017">Department of Pediatric Neurology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 
<country>Bangladesh</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-jer-19017">Corresponding author: Kanij Fatema, FCPS, Department of Pediatric Neurology, Bangabandhu Sheikh Mujib Medical University, House 37, Road 10A, Dhanmondi, Dhaka 1209, Bangladesh, Tel. +8801713097751, Fax. +8801713097751, E-mail; <email>mailmonami@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>9</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>151</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Korean Epilepsy Society</copyright-statement>
<copyright-year>2019</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Early infantile epileptic encephalopathy type 13 is a severe form of epilepsy caused by mutations in the sodium channel 8 alpha (SCN8A) gene. This gene encodes the neuronal voltage-gated sodium channel which plays vital role in neuronal excitability. Here we present two cases with SCN8A encephalopathy. Both cases had mutation in p.Arg1872Gin the SCN8A gene, which was detected by targeted next generation sequencing. Case 1 was a 14-month old boy, who had a normal birth history with normal development up to 6 months and then developed repeated generalized seizure, which was nonresponsive to multiple antiepileptic drugs. He also had neuroregression and dystonia. His electroencephalogram (EEG) showed progressive background abnormality with burst suppression pattern. His metabolic panel was normal and had partial response to carbamazepine. The second case was for an 11-month old boy with the onset of seizure at the age of 7 months. Seizure was generalized, resistant to multiple antiepileptic drugs. He had developmental delay from beginning, no movement disorder. EEG showed focal discharge from left temporal and occipital region. He showed partial response to oxcarbazepine. Our cases had similarities with the previously reported cases. The detailed discussion of our cases would contribute to early detection and targeted treatment of SCN8A encephalopathy. This also gives special emphasis on a genetic test in infants with intractable epilepsy, movement disorder and developmental delay.</p>
</abstract>
<kwd-group>
<kwd>Sodium voltage-gated channel alpha subunit 8 (SCN8A)</kwd>
<kwd>Epileptic encephalopathy</kwd>
<kwd>Epilepsy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Early infantile epileptic encephalopathy (EIEE) is a severe form of epilepsy, which affects children in early infancy and causes devastating neurological disorders. They have variable genetic heterogeneity.<xref ref-type="bibr" rid="b1-jer-19017">1</xref>,<xref ref-type="bibr" rid="b2-jer-19017">2</xref> Sodium voltage-gated channel alpha subunit 8 (SCN8A) mutation causing EIEE type 13 comprises 1% of patients of epileptic encephalopathy.<xref ref-type="bibr" rid="b3-jer-19017">3</xref> SCN8A-encephalopathies are autosomal dominant disorders, which is caused by <italic>de novo</italic> gain-of-function missense mutations in the gene. This gene is part of the voltage gated sodium channels (VGSCs) gene family.<xref ref-type="bibr" rid="b4-jer-19017">4</xref>,<xref ref-type="bibr" rid="b5-jer-19017">5</xref> VGSCs plays important role in controlling neuronal excitability. They are primarily expressed in the central nervous system and mutation causes epilepsy.<xref ref-type="bibr" rid="b6-jer-19017">6</xref>–<xref ref-type="bibr" rid="b9-jer-19017">9</xref></p>
<p>SCN8A gene is located at human chromosome 12q13.13. The coding sequence (170 Kb) of this gene contains 27 exons which encodes a protein of 1980 amino acid residues, intolerant to variations.<xref ref-type="bibr" rid="b10-jer-19017">10</xref>–<xref ref-type="bibr" rid="b12-jer-19017">12</xref> Thus a minor deviation in the properties of the ion channel proteins can lead to significant functional defects.<xref ref-type="bibr" rid="b13-jer-19017">13</xref> SCN8A encodes the Na<sub>v</sub>1.6α subunit of VGSCs, which is highly expressed in the initial axonal segment and nodes of Ranvier of myelinated axons, and it is responsible for generation of action potential and conduction.<xref ref-type="bibr" rid="b14-jer-19017">14</xref>–<xref ref-type="bibr" rid="b16-jer-19017">16</xref></p>
<p>The clinical presentation of SCN8A mutation is variable. The common features are intractable epilepsy, which is evident in infancy along with developmental stagnation or delay. However, some cases are milder, which presents as benign infantile seizures and paroxysmal choreoathetosis. While some cases present only with intellectual disability.<xref ref-type="bibr" rid="b14-jer-19017">14</xref>–<xref ref-type="bibr" rid="b16-jer-19017">16</xref></p>
<p>In this research, we presented that the clinical and genetic features of two cases of SCN8A encephalopathy, presented with intractable epilepsy and developmental delay.</p>
</sec>
<sec sec-type="cases">
<title>Case Report</title>
<sec>
<title>Case 1</title>
<p>A 14 months old male child, only issue of his nonconsanguineous parents, partially immunized presented with recurrent attacks of seizure since 6 months of age. Seizure was generalized tonic clonic in nature with upward rolling of eyes and persisted for about 1 to 2 minutes, occurring four to five times per day. He was born with normal vaginal delivery at term, with average birth weight. There was no adverse event in the perinatal period. Before the onset of seizure, his development was normal for his age. Since then, there was progressive regression of achieved milestones and he lost his neck control, social smile and was least responsive to surroundings. Along with this, he also developed involuntary movement manifested by posturing mainly in limbs, which occurred during awake period and subsided in sleep.</p>
<p>There was no history excessive vomiting, abnormal urine or body odor, loss of consciousness, fever, feeding difficulty, respiratory tract infection, skin changes etc. On examination the child was conscious, there was no facial dysmorphism. His vitals were within normal limit and he was anthropometrically well thrived. Bacillus Calmette-Guérin (BCG) mark was present without any skin stigmata. Developmental assessment revealed that there was no neck control or social smile but the child could fix, follow and localize sound, but no babbling. On nervous system examination, there was hypertonia in all four limbs with exaggerated deep tendon reflexes and planter was extensor. He also had dystonia in both upper and lower limbs. Other systemic examinations revealed nothing abnormal and ophthalmological examination was also normal. Psychological examination using a third edition of the Bayley Scales of Infant and Toddler Development (BSID-III) revealed cognition was around 2 months, gross motor 3 months and fine motor 3 months level.</p>
<p>A complete blood count test showed hemoglobin level of 12 g/dL with total leukocyte count of 10,000/cm<sup>2</sup> and platelet of 450,000/cm<sup>2</sup>. Initial 2 electroencephalogram (EEG) showed focal discharges from frontal and temporal areas with apparently normal background. But in the last EEG, there was burst of epileptic discharges, arising from frontal and temporal regions with severe background abnormality evident by attenuation and slowing mostly in posterior regions. The brain magnetic resonance imaging (MRI) showed cortical atrophy. Serum ammonia was normal, serum lactate was normal, urinary ketone body was negative, <italic>random blood sugar (</italic>RBS) was normal, a<italic>rterial blood gas</italic> (ABG) was normal. <italic>Tandem mass spectrometer (</italic>TMS) was within normal limits, biotinidase enzyme activity was within normal limits and <italic>gas chromatography mass spectrometry (</italic>GCMS) was within normal limits.</p>
<p>Genetic study with clinical exome sequencing revealed there was mutation on SCN8A(+) at exon 27, variant c.5615G&gt;A (p.Arg1872Gin), zygosity heterozygous. Disease as per Online Mendelian Inheritance in Man (OMIM) was EIEE type 13, inheritance-autosomal dominant, classification-likely pathogenic.</p>
<sec>
<title>Treatment</title>
<p>He was treated with phenobarbitone, levetiracetam, prednisolone, adenocorticotropic hormone, vigabatrine and sodium valproate, but seizure was not controlled. Later he was treated with carbamazepine, which caused the 50% control of the seizure. For dystronia, tri-hexyphenydyl was given to the child and for developmental delay, physiotherapy was given.</p>
</sec>
</sec>
<sec>
<title>Case 2</title>
<p>An 11 months old male child, who had the 3rd issue of his non consanguineous parents partially immunized presented with recurrent attacks of seizure since 7 months of age which was generalized tonic clonic in nature with upward rolling of eyeball, occurred 5–6 times/day, each episode persisted for about 1–2 minutes.</p>
<p>He had the delayed developmental milestone manifested by neck control, achieved at 8 months old, and is unable to sit until the present. His birth history was uneventful. He had a history of unexplained sib death in neonatal period and his mother had a history of epilepsy in childhood. There was no medical history of excessive vomiting, abnormal urine or body odor, unconsciousness, fever, feeding abnormality, respiratory tract infections, skin manifestation, trauma, altered sensorium etc.</p>
<p>On examinations the child was conscious, without any facial dysmorphism. His vitals were within normal and he was anthropometrically well thrived. BCG mark was present without any skin stigmata. Developmental assessment revealed global developmental delay. On nervous system examination, there was hypertonia with exaggerated deep tendon reflexes in all four limbs. Other systemic examinations revealed nothing abnormal. Ophthalmological examination was normal.</p>
<sec>
<title>Investigations</title>
<p>CBC was normal, EEG showed focal epileptiform discharge arising from left temporal and occipital region, MRI of brain showed cortical atrophy, serum ammonia was normal, serum lactate, was normal, urinary ketone body was negative, RBS was normal, ABG was normal. TMS was within normal limits, Biotinidase enzyme activity was within normal limits. GCMS was normal.</p>
<p>Genetic study with clinical exome sequencing revealed SCN8A(+) mutation at exon 27, variant c.5615G&gt;A (p.Arg1872Gin), zygositiy-heterozygous. Disease as per OMIM was EIEE type 13, inheritance-autosomal dominant, classification-likely pathogenic.</p>
</sec>
<sec>
<title>Treatment</title>
<p>He was treated with phenobarbitone, levetiracetam, vigabatrine, but there was minimal response. There was partial response the oxcarbazepine.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>SCN8A encephalopathy has been first described in 2012 and several cases have been identified till date.<xref ref-type="bibr" rid="b17-jer-19017">17</xref> This encephalopathy is also known as EIEE type 13. The patients present with drug resistant seizure between age 3 and 7 months (mean age, 5 months; range, 1 day to 18 months).<xref ref-type="bibr" rid="b1-jer-19017">1</xref>,<xref ref-type="bibr" rid="b18-jer-19017">18</xref>,<xref ref-type="bibr" rid="b19-jer-19017">19</xref> The seizure has no definite pattern but is often provoked. The common seizures are epileptic spasm, tonic, atonic, myoclonic, focal and absence seizure.<xref ref-type="bibr" rid="b1-jer-19017">1</xref></p>
<p>The patients also present with developmental delay and/or stagnation. For the half of the patients, development is normal prior to the onset of seizure. In addition to that, there are movement disorder like ataxia, choreoathetosis, hypotonia, spasticity, dystonia and etc.<xref ref-type="bibr" rid="b1-jer-19017">1</xref>,<xref ref-type="bibr" rid="b12-jer-19017">12</xref> Some patients present with behavioral disorder like autistic feature and etc.<xref ref-type="bibr" rid="b18-jer-19017">18</xref>,<xref ref-type="bibr" rid="b19-jer-19017">19</xref> Whereas in literature some patients are found with milder phenotype such as early benign focal epilepsy, well controlled seizure, mild tremor, ataxia, motor delay and normal cognitive delay.<xref ref-type="bibr" rid="b20-jer-19017">20</xref></p>
<p>Clinically, two of our patients’ phenotyepe are similar to the typical features of EIEE type 13. The age of onset is around 5 to 7 months. In one patient, the prior development was normal and in another, there was delay. In both of the patients, seizure was difficult to control and so multiple antiepileptic drugs were given. In one patient, movement disorder was present in the form of dystonia. In both of the infants, spasticity and global developmental delay were present. None of the patients had behavioral disorder like autism.</p>
<p>EEG findings are variable in EIEE type 13. Early EEG may be normal or show focal or multifocal epileptic discharges. EEG features change over time and the background shows progressive slowing. The epileptic discharges are most prominent in temporal regions, comprised of spike or spike followed by slow waves. There may be almost continuous slowing in temporal, parietal, and occipital regions. Superimposed beta waves and bilateral asynchronous spike or sharp waves may be found.<xref ref-type="bibr" rid="b1-jer-19017">1</xref> There was progressive deterioration of the background in case 1, and also initially there was focal discharges, which turned into burst suppression pattern later on. In case 2, EEG showed focal epileptic discharges arising from occipital and temporal region; here the background was not uninterrupted.</p>
<p>Cranial MRI is not specific in SCN8A encephalopathy; usually it is normal in the most of the cases at the onset of seizure. However, there may be cortical atrophy or corpus callosum abnormality in some cases. There may be progressive cerebral or cerebellar atrophy in follow up imaging.<xref ref-type="bibr" rid="b1-jer-19017">1</xref>,<xref ref-type="bibr" rid="b21-jer-19017">21</xref> In both of our cases cortical atrophy was found in MRI.</p>
<p>The final diagnosis is done by a genetic study. In targeted next generation sequencing, we identified heterozygous mutation in exon 27 of the SCN8A gene: c.5615G&gt;A (p.Arg1872Gin) in cases 1 and 2. It represents a neocleotide substitution of guanine with adenine in chromosome 12, which results in amino acid substitution from argi-nine to glutamine at position 1872 of the protein, which is reported as a mutational hotspot. According to several groups of authors the amino acid substitution is severely damaging to the structure of the sodium channel.<xref ref-type="bibr" rid="b12-jer-19017">12</xref></p>
<p>In previous literature it has been found that there is no obvious correlation between the positions of an SCN8A pathogenic variant and the seizure onset, seizure type or clinical severity. In one study significant similarity of phenotype was found in two unrelated individuals with same <italic>de novo</italic> pathogenic variant.<xref ref-type="bibr" rid="b21-jer-19017">21</xref>,<xref ref-type="bibr" rid="b22-jer-19017">22</xref> However, in another study same pathogenic variant manifested different ages of the onset and disease severity.<xref ref-type="bibr" rid="b12-jer-19017">12</xref></p>
<p>Penetrance of SCN8A encephalopathy which is identified until the present are <italic>de novo</italic> or inherited from either parent with a somatic mosaic variant, which is pathogenic and included in the germline. Also no pathogenic variant has been identified in an unaffected individual.<xref ref-type="bibr" rid="b23-jer-19017">23</xref> The majority of the SCN8A mutation, which are found in genetic test, are gain-of-function causing the Na<sub>v</sub>1.6 channel to be hyperactive, and so there is excessive neuronal firing causing seizure. This mutation is also responsible for the intellectual disability as it has a primary neurodegenerative effect.<xref ref-type="bibr" rid="b24-jer-19017">24</xref>–<xref ref-type="bibr" rid="b26-jer-19017">26</xref></p>
<p>Both our patients have been treated with multiple antiepileptic drugs before admission. Partial response has been noted in both cases with carbamazepine and oxcarbazepine. Literature has suggested that patients with SCN8A encephalopathy respond to the sodium channel blockers such as phenytoin, valproate, carbamazepine, lacosomide, lamotrigine, rufinamide and oxcarbazepine.<xref ref-type="bibr" rid="b1-jer-19017">1</xref>,<xref ref-type="bibr" rid="b27-jer-19017">27</xref> In case 1, the patient did not respond to valproate but responded to carbamazepine partially. The case 2 did not respond to vigabatrin, phenobarbitone but responded partially to oxcarbazepine. In previous studies, most of the patients were maintained on multiple medications for partial seizure control.<xref ref-type="bibr" rid="b28-jer-19017">28</xref> Boerma et al.<xref ref-type="bibr" rid="b28-jer-19017">28</xref> reported four severely affected SCN8A encephalopathy patients who were successfully treated with high dose of phenytoin. Both phenytoin and carbamazepine is sodium channel blocker but the affinity of carbamazepine for sodium channel is about three times lower than phenytoin.<xref ref-type="bibr" rid="b29-jer-19017">29</xref> We did not use phenytoin for any of our cases due to its side effects.</p>
<p>SCN8A encephalopathy has some consistent clinical and electrographic findings. Thus, in any case of intractable epilepsy in infancy with movement disorder and neuroregression or intellectual disability, where there is no definite etiology, a genetic test is suggested. This will be helpful in the precision medicine of the case as well as there will be a scope for genetic counseling for further pregnancy.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-jer-19017">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Gardella</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The phenotypic spectrum of SCN8A encephalopathy</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<fpage>480</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">25568300</pub-id>
</element-citation>
</ref>
<ref id="b2-jer-19017">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagnon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Hounshell</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy</article-title>
<source/>Ann Clin Transl Neurol
          <year>2015</year>
<volume>3</volume>
<fpage>114</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">26900580</pub-id>
</element-citation>
</ref>
<ref id="b3-jer-19017">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Helman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SCN8A encephalopathy: research progress and prospects</article-title>
<source/>Epilepsia
          <year>2016</year>
<volume>57</volume>
<fpage>1027</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">27270488</pub-id>
</element-citation>
</ref>
<ref id="b4-jer-19017">
<label>4</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Mantegazza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rusconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cestele</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mutations of ion channels in genetic epilepsies</article-title>
<person-group person-group-type="editor">
<name>
<surname>Striano</surname>
<given-names>P</given-names>
</name>
</person-group>
<source/>Epilepsy towards the next decade: new trends and hopes in epileptology
          <publisher-loc>Basel</publisher-loc>
<publisher-name>Springer</publisher-name>
<year>2015</year>
<fpage>15</fpage>
<lpage>34</lpage>
</element-citation>
</ref>
<ref id="b5-jer-19017">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Lera Ruiz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications</article-title>
<source/>J Med Chem
          <year>2015</year>
<volume>58</volume>
<fpage>7093</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">25927480</pub-id>
</element-citation>
</ref>
<ref id="b6-jer-19017">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Dibbens</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?</article-title>
<source/>Brain Dev
          <year>2009</year>
<volume>31</volume>
<fpage>394</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">19203856</pub-id>
</element-citation>
</ref>
<ref id="b7-jer-19017">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yasumoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurahashi</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical spectrum of SCN2A mutations</article-title>
<source/>Brain Dev
          <year>2012</year>
<volume>34</volume>
<fpage>541</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">22029951</pub-id>
</element-citation>
</ref>
<ref id="b8-jer-19017">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Osaka</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome</article-title>
<source/>Neurology
          <year>2013</year>
<volume>81</volume>
<fpage>992</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23935176</pub-id>
</element-citation>
</ref>
<ref id="b9-jer-19017">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanoye</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Gurnett</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>George</surname>
<given-names>AJ</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Kearney</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Novel SCN3A variants associated with focal epilepsy in children</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>62</volume>
<fpage>313</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">24157691</pub-id>
</element-citation>
</ref>
<ref id="b10-jer-19017">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plummer</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Galt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exon organization, coding sequence, physical mapping, and polymorphic intragenic markers for the human neuronal sodium channel gene SCN8A</article-title>
<source/>Genomics
          <year>1998</year>
<volume>54</volume>
<fpage>287</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">9828131</pub-id>
</element-citation>
</ref>
<ref id="b11-jer-19017">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Brien</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability</article-title>
<source/>Front Genet
          <year>2013</year>
<volume>4</volume>
<fpage>213</fpage>
<pub-id pub-id-type="pmid">24194747</pub-id>
</element-citation>
</ref>
<ref id="b12-jer-19017">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagnon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy</article-title>
<source/>Front Neurol
          <year>2015</year>
<volume>6</volume>
<fpage>104</fpage>
<pub-id pub-id-type="pmid">26029160</pub-id>
</element-citation>
</ref>
<ref id="b13-jer-19017">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kearney</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Sodium channel mutations in epilepsy and other neurological disorders</article-title>
<source/>J Clin Invest
          <year>2005</year>
<volume>115</volume>
<fpage>2010</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">16075041</pub-id>
</element-citation>
</ref>
<ref id="b14-jer-19017">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzoumaka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tischler</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sangameswaran</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eglen</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Novakovic</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>Differential distribution of the tetrodotoxin-sensitive Rpn4/NaCh6/Scn8a sodium channel in the nervous system</article-title>
<source/>J Neurosci Res
          <year>2000</year>
<volume>60</volume>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">10723066</pub-id>
</element-citation>
</ref>
<ref id="b15-jer-19017">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gardella</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Møller</surname>
<given-names>RS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation</article-title>
<source/>Ann Neurol
          <year>2016</year>
<volume>79</volume>
<fpage>428</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">26677014</pub-id>
</element-citation>
</ref>
<ref id="b16-jer-19017">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trudeau</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ranum</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>527</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">16236810</pub-id>
</element-citation>
</ref>
<ref id="b17-jer-19017">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atanasoska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vazharova</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SCN8A p. Arg1872Gln mutation in early infantile epileptic encephalopathy type 13: review and case report</article-title>
<source/>Biotechnol Biotechnol Equip
          <year>2018</year>
<volume>32</volume>
<fpage>1345</fpage>
<lpage>51</lpage>
</element-citation>
</ref>
<ref id="b18-jer-19017">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arafat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unexplained early infantile epileptic encephalopathy in Han Chinese children: next-generation sequencing and phenotype enriching</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>46227</fpage>
<pub-id pub-id-type="pmid">28387369</pub-id>
</element-citation>
</ref>
<ref id="b19-jer-19017">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horvath</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Demos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shyr</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: a potential treatment target?</article-title>
<source/>Mol Genet Metab
          <year>2016</year>
<volume>117</volume>
<fpage>42</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">26647175</pub-id>
</element-citation>
</ref>
<ref id="b20-jer-19017">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagnasco</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dassi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Blé</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vigliano</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A relatively mild phenotype associated with mutation of SCN8A</article-title>
<source/>Seizure
          <year>2018</year>
<volume>56</volume>
<fpage>47</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">29432985</pub-id>
</element-citation>
</ref>
<ref id="b21-jer-19017">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jayapal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jungbluth</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lascelles</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation</article-title>
<source/>Seizure
          <year>2015</year>
<volume>26</volume>
<fpage>69</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">25799905</pub-id>
</element-citation>
</ref>
<ref id="b22-jer-19017">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaher</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Nõukas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nikopensius</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders</article-title>
<source/>J Child Neurol
          <year>2014</year>
<volume>29</volume>
<fpage>NP202</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">24352161</pub-id>
</element-citation>
</ref>
<ref id="b23-jer-19017">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Hammer</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Wagnon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mefford</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title><italic>SCN8A</italic>-related epilepsy with encephalopathy</article-title>
<person-group person-group-type="editor">
<name>
<surname>Adam</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Ardinger</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Pagon</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<source/>GeneReviews®
          <publisher-loc>Seattle</publisher-loc>
<publisher-name>University of Washington</publisher-name>
<year>2020</year>
</element-citation>
</ref>
<ref id="b24-jer-19017">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo gain-of function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy</article-title>
<source/>J Med Genet
          <year>2015</year>
<volume>52</volume>
<fpage>330</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">25725044</pub-id>
</element-citation>
</ref>
<ref id="b25-jer-19017">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estacion</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Conravey</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>69</volume>
<fpage>117</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">24874546</pub-id>
</element-citation>
</ref>
<ref id="b26-jer-19017">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okayama</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Electroclinical features of epileptic encephalopathy caused by SCN8A mutation</article-title>
<source/>Pediatr Int
          <year>2015</year>
<volume>57</volume>
<fpage>758</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">25951352</pub-id>
</element-citation>
</ref>
<ref id="b27-jer-19017">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>In response: SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>1320</fpage>
<pub-id pub-id-type="pmid">26235739</pub-id>
</element-citation>
</ref>
<ref id="b28-jer-19017">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boerma</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>van de Broek</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach</article-title>
<source/>Neurotherapeutics
          <year>2016</year>
<volume>13</volume>
<fpage>192</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">26252990</pub-id>
</element-citation>
</ref>
<ref id="b29-jer-19017">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuo</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications</article-title>
<source/>Mol Pharmacol
          <year>1997</year>
<volume>51</volume>
<fpage>1077</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">9187275</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>